Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update comparing giredestrant plus palbociclib with letrozole plus palbociclib in ER-positive, HER2-negative locally advanced or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Giredestrant (giredestrant)
• Letrozole (letrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING